Difference between revisions of "Hypericum-mianserine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{ Drugswitch | from = hypericum | to = mianserine | stop = * Administration of hypericum can be stopped abruptly. | start = * '''Day 1-7:''' a wash-out period of one week i...')
(No difference)

Revision as of 13:40, 7 May 2009

Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort
Mianserine
Type Antidepressant
Group other
links
PubChem 4184
PubMed Mianserine
Kompas (Dutch) Mianserine
Wikipedia Mianserine

Switch medication from hypericum to mianserine.[1] [2]

Nietinrijdenbord.png Stop hypericum
  • Administration of hypericum can be stopped abruptly.
Eenrichtingbord.png Start mianserine
  • Day 1-7: a wash-out period of one week is necessary.
  • Day 8: start administration of mianserine in a dosage of 30 mg/day.
  • If necessary, increase dosage of mianserine to 60 mg/day.
Infobord.png More information
  • Occurence of the serotonin syndrome is theoretically possible.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.